ProCE Banner Activity

WSG-ADAPT: Trastuzumab Emtansine ± ET vs Trastuzumab + ET in HER2+/HR+ Early Breast Cancer

Slideset Download
Conference Coverage
Twelve weeks of trastuzumab emtansine therapy increased the rate of pCR in women with HER2+/HR+ early breast cancer compared with trastuzumab plus endocrine therapy.

Released: December 15, 2015

Expiration: December 13, 2016

No longer available for credit.

Share

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Genentech BioOncology

Novartis Pharmaceuticals Corporation